BRAF and melanoma: Furthermore, we found that Dabrafenib-treated BRAF-mutant melanoma cell lines exhibited larger ∣loge(BF)∣ than other Dabrafenib-treated cell lines (average ∣loge(BF)∣ of 0.763 vs 0.668 for other cell lines), clustering with the Trametinib-treated cell lines as reported in the MIX-Seq study (Fig. 2c and SFig. 6d).